These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 23439496)

  • 1. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection.
    Wooddell CI; Rozema DB; Hossbach M; John M; Hamilton HL; Chu Q; Hegge JO; Klein JJ; Wakefield DH; Oropeza CE; Deckert J; Roehl I; Jahn-Hofmann K; Hadwiger P; Vornlocher HP; McLachlan A; Lewis DL
    Mol Ther; 2013 May; 21(5):973-85. PubMed ID: 23439496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes.
    Sebestyén MG; Wong SC; Trubetskoy V; Lewis DL; Wooddell CI
    Methods Mol Biol; 2015; 1218():163-86. PubMed ID: 25319651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
    Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
    Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus.
    Chen CC; Chang CM; Sun CP; Yu CP; Wu PY; Jeng KS; Hu CP; Chen PJ; Wu JC; Shih CH; Gershwin ME; Tao MH
    Gene Ther; 2012 Jan; 19(1):25-33. PubMed ID: 21562593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo.
    Wong SC; Klein JJ; Hamilton HL; Chu Q; Frey CL; Trubetskoy VS; Hegge J; Wakefield D; Rozema DB; Lewis DL
    Nucleic Acid Ther; 2012 Dec; 22(6):380-90. PubMed ID: 23181701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses.
    Trubetskoy VS; Griffin JB; Nicholas AL; Nord EM; Xu Z; Peterson RM; Wooddell CI; Rozema DB; Wakefield DH; Lewis DL; Kanner SB
    Nucleic Acids Res; 2017 Feb; 45(3):1469-1478. PubMed ID: 28180327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.
    Yamamoto N; Sato Y; Munakata T; Kakuni M; Tateno C; Sanada T; Hirata Y; Murakami S; Tanaka Y; Chayama K; Hatakeyama H; Hyodo M; Harashima H; Kohara M
    J Hepatol; 2016 Mar; 64(3):547-55. PubMed ID: 26505121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.
    Gish RG; Yuen MF; Chan HL; Given BD; Lai CL; Locarnini SA; Lau JY; Wooddell CI; Schluep T; Lewis DL
    Antiviral Res; 2015 Sep; 121():97-108. PubMed ID: 26129970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y; Li Z; Li L; Li J; Liu X; Li W
    Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites.
    Sun D; Rösler C; Kidd-Ljunggren K; Nassal M
    J Hepatol; 2010 Jun; 52(6):817-26. PubMed ID: 20400195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA.
    Chen CC; Ko TM; Ma HI; Wu HL; Xiao X; Li J; Chang CM; Wu PY; Chen CH; Han JM; Yu CP; Jeng KS; Hu CP; Tao MH
    Gene Ther; 2007 Jan; 14(1):11-9. PubMed ID: 16929350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo.
    Li B; Sun S; Li M; Cheng X; Li H; Kang F; Kang J; Dörnbrack K; Nassal M; Sun D
    Antiviral Res; 2016 Oct; 134():117-129. PubMed ID: 27591142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice.
    Ebert G; Poeck H; Lucifora J; Baschuk N; Esser K; Esposito I; Hartmann G; Protzer U
    Gastroenterology; 2011 Aug; 141(2):696-706, 706.e1-3. PubMed ID: 21684282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs.
    Marimani MD; Ely A; Buff MC; Bernhardt S; Engels JW; Scherman D; Escriou V; Arbuthnot P
    J Control Release; 2015 Jul; 209():198-206. PubMed ID: 25937322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver.
    Dusséaux M; Masse-Ranson G; Darche S; Ahodantin J; Li Y; Fiquet O; Beaumont E; Moreau P; Rivière L; Neuveut C; Soussan P; Roingeard P; Kremsdorf D; Di Santo JP; Strick-Marchand H
    Gastroenterology; 2017 Dec; 153(6):1647-1661.e9. PubMed ID: 28851562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
    Chen X; Qian Y; Yan F; Tu J; Yang X; Xing Y; Chen Z
    Eur J Pharmacol; 2013 Dec; 721(1-3):86-95. PubMed ID: 24099962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting the RNA interference pathway to counter hepatitis B virus replication.
    Arbuthnot P; Carmona S; Ely A
    Liver Int; 2005 Feb; 25(1):9-15. PubMed ID: 15698393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hepatitis B virus and induction of hepatoma cell apoptosis by ASGPR-directed delivery of shRNAs.
    Ma J; Huang C; Yao X; Shi C; Sun L; Yuan L; Lei P; Zhu H; Liu H; Wu X; Ning Q; Zhou C; Shen G
    PLoS One; 2012; 7(10):e46096. PubMed ID: 23094023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
    Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
    Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient delivery of HBV NLS siRNAs into HepG2.2.15 cells for HBV inhibition through novel recombinant preS1‑tP proteins.
    Zeng Y; Li Z; Shang J; Kang Y
    Int J Mol Med; 2018 Aug; 42(2):1181-1189. PubMed ID: 29786106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.